NCT03106038View on ClinicalTrials.gov

Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 26, 2017

Primary Completion Date

November 19, 2018

Study Completion Date

November 19, 2018

Conditions
Intraoperative Ureter Injury
Interventions
DRUG

Nerindocianine for Injection

Procedure: routine minimally invasive pelvic surgery.

Trial Locations (1)

35233

UAB Women & Infants Center, Birmingham

All Listed Sponsors
lead

Li-Cor, Inc.

INDUSTRY

NCT03106038 - Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery | Biotech Hunter | Biotech Hunter